Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL).

Francine M. Foss,Christiane Querfeld,Pierluigi Porcu,Youn H. Kim,Theresa R. Pacheco,Ahmad Halwani,Jennifer DeSimone,Basem M. William,Anita Seto,Judy Ruckman,Michele L Landry,Aimee L. Jackson,Linda A Pestano,Brent Dickinson,Mark Sanseverino,David M. Rodman,Paul Rubin,Gilad Shalag Gordon,William Marshall

Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL).

2017

Francine M. Foss
Christiane Querfeld
Pierluigi Porcu
Youn H. Kim
Theresa R. Pacheco
Ahmad Halwani
Jennifer DeSimone
Basem M. William
Anita Seto
Judy Ruckman
Michele L Landry
Aimee L. Jackson
Linda A Pestano
Brent Dickinson
Mark Sanseverino
David M. Rodman
Paul Rubin
Gilad Shalag Gordon
William Marshall

7564Background: MRG-106 is an oligonucleotide inhibitor of miR-155, a microRNA with a strong mechanistic link to CTCL, selected based on its activity in mycosis fungoides (MF) cell lines. The objec...

Keywords:

Pathology
Cutaneous T-cell lymphoma
Cancer research
microRNA
Medicine
Mycosis fungoides
in patient
Cell culture

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations